Actively Recruiting
Comparing Oral Fluconazole and Oral Itraconazole for Treating Pityriasis Versicolor in Adults Aged 18 to 50
Led by Khyber Teaching Hospital · Updated on 2025-04-10
106
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of two oral antifungal drugs, fluconazole and itraconazole, for treating pityriasis versicolor, a common fungal infection affecting the outer layers of the skin. The study aims to compare how well these two systemic treatments work to control the infection. This is a randomized, phase 4 clinical trial sponsored by Khyber Teaching Hospital. Participants are randomly assigned to one of two groups. Group A receives oral fluconazole at a dose of 300 mg once weekly for two weeks. Group B takes oral itraconazole at 100 mg twice daily for five days. The treatments are given as pills to assess their effects on the fungal infection during the study period. During the trial, participants will be monitored for up to eight weeks to measure the effectiveness of the treatment. Researchers will evaluate the improvements in the fungal infection and track any side effects or safety concerns. The study includes adults aged 18 to 50 years diagnosed with pityriasis versicolor, and participants will be followed to understand how each drug performs over time.
CONDITIONS
Brief Title
Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here